

**Amendments to the Drawings under 37 C.F.R. 1.121(d)**

There are no amendments to the drawings at this time.

**Remarks/Arguments**

The Applicant would like to take this opportunity to thank the examiner for the informative and productive interview of October 5, 2010. Pursuant to the topics discussed in the interview, and in further response to the Office Action of March 3, 2010, applicant submits this Supplemental Amendment.

Upon entry of this Amendment, claims 1, 8, 11-15, 17, 20, 25-26, 29-40, and 85-103 will be pending. Claims 27-28, 41-71, 82-84 have been withdrawn. Claims 2-7, 9-10, 16, 18, 19, 21-24, and 72-81 were cancelled without prejudice to or disclaimer of the subject matter therein. Claims 1, 12-14, 29-33, and 35 are amended. Claims 96-103 are new. Applicants reserve the right to prosecute the subject matter of the withdrawn and cancelled claims in a continuation, continuation-in-part or divisional application.

Claim 1 has been amended to refine the claim language.

Claims 12-14 have been amended to remove inadvertently included redundant language. Claim 14 is further amended to remove an inadvertently included hyphen.

Claims 29-33 have been amended to revise the word particle to microparticle.

Claim 35 is amended to refine the claim language to recite a single beta particle and a gamma particle selected from a Markush group.

Claim 96 is new and further defines the invention and includes the feature wherein the dendritic polymer linking carrier is a poly(methyl methacrylate) (PMMA) dendrimer.

Claim 97 is new and further defines the invention wherein the microparticle incorporates a dendritic polymer having a plurality of terminal functional groups to which both beta and gamma emitting chelated radiopharmaceuticals are attached.

Claim 98 is new and further defines the invention wherein the microparticle incorporates a plurality of dendritic polymers each having a terminal functional group to which either a beta or gamma emitting chelated radiopharmaceuticals is attached.

Claim 99 is new and further defines the invention wherein the invention is a kit for for producing the particulate material for radiopharmaceutical use.

Claims 100-103 are new and are each dependant from independent claims 97, 98, and 99, and further define the scope of the invention.

**Conclusion**

Applicants believe that all of the stated grounds for objection and rejection have been properly traversed, accommodated, or rendered moot. Applicants, therefore, respectfully request that the Examiner reconsider all presently outstanding rejections and objections and request that they be withdrawn. Applicants believe that the present application is in condition for allowance. Prompt and favorable consideration of this Amendment and Reply is respectfully requested.

Respectfully submitted,



November 12, 2010

---

Todd L. Juneau  
Reg. No. 40669  
JUNEAU PARTNERS  
USPTO Customer 50438  
(703)548-3569  
todd@juneaupartners.com

---

Date